Le Lézard
Classified in: Health
Subjects: BLK, CSR

Blue Faery Continues Its Love Your Liver Campaign During Black History Month


Blue Faery is pleased to announce that its annual liver disease and cancer awareness campaign will continue in 2024 during Black History Month. This will be the third consecutive year of this life-saving and award-winning effort.

BIRMINGHAM, Ala., Feb. 1, 2024 /PRNewswire/ -- Black/African Americans are 50% more likely to get liver cancer than the general population, and incidence rates are climbing. The Love Your Liver campaign provides community members with convenient opportunities to learn more about their unique liver cancer risks and how to actively manage them. Type 2 diabetes and hepatitis C can both lead to liver cancer, so those in the Black/African American community who currently have or previously had one or both of those diseases are at higher risk for liver cancer. Both type 2 diabetes and hepatitis C are preventable and treatable, so education and early detection are vital to improving survival rates.

Love Your Liver Live, a Black History Month Community Event series, kicks off on February 22, 2024, at 7 p.m. ET with a live, virtual education workshop featuring Miriam Atkins, MD, a medical oncologist with multispecialty clinics in Georgia and South Carolina. The second live, virtual educational workshop will be on February 29, 2024, at 8 p.m. ET and features Gia Landry, MD, a hepatologist with Ochsner in Baton Rouge. These free virtual workshops allow community members to learn about relevant liver cancer risks and how to manage them from a trusted local physician.

"Liver cancer cases continue to swell in the Black community," said Dr. Landry. "It is important that community members see doctors and healthcare professionals who understand their cultural perspectives and focus on their unique risk factors. Too many members of our community are dying from preventable diseases, and we have the power to change these statistics."

Blue Faery's mission is to prevent, treat, and cure primary liver cancer, specifically hepatocellular carcinoma (HCC), through research, education, and advocacy. Blue Faery hosts an online Liver Cancer Community for patients and caregivers. Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer (HCC). Blue Faery has many educational and advocacy programs, including Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Blue Faery


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: